What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?

Robert E.J. Ryder; Ralph A. Defronzo; Bob Ryder

doi:10.15277/bjd.2017.136

What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?

Robert E.J. Ryder, Ralph A. Defronzo, Bob Ryder

Department of Medicine

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	89-92
Number of pages	4
Journal	British Journal of Diabetes and Vascular Disease
Volume	17
Issue number	3
DOIs	https://doi.org/10.15277/bjd.2017.136
State	Published - 2017

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Cardiology and Cardiovascular Medicine

Access to Document

10.15277/bjd.2017.136

Cite this

What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives? / Ryder, Robert E.J.; Defronzo, Ralph A.; Ryder, Bob.

In: British Journal of Diabetes and Vascular Disease, Vol. 17, No. 3, 2017, p. 89-92.

Research output: Contribution to journal › Review article › peer-review

@article{264dedb17b6244b68612bbd85ca95caf,

title = "What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?",

author = "Ryder, {Robert E.J.} and Defronzo, {Ralph A.} and Bob Ryder",

year = "2017",

doi = "10.15277/bjd.2017.136",

language = "English (US)",

volume = "17",

pages = "89--92",

journal = "British Journal of Diabetes and Vascular Disease",

issn = "1474-6514",